LOGIN  |  REGISTER
Recursion
Chimerix

Thermo Fisher Scientific Releases 2023 Corporate Social Responsibility Report

May 28, 2024 | Last Trade: US$529.42 5.00 -0.94
  • Report highlights company’s commitments to all of its stakeholders and society

WALTHAM, Mass. / May 28, 2024 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today released its 2023 Corporate Social Responsibility (CSR) report, which provides an overview of the company, its CSR priorities and the progress enabled by its more than 120,000 colleagues.

“Thermo Fisher is driven by a profound Mission – to enable our customers to make the world healthier, cleaner, and safer,” said Marc N. Casper, chairman, president and chief executive officer of Thermo Fisher Scientific. “We also understand our obligation goes beyond enabling our customers’ success and extends to making the world a better place by supporting our communities, being a good steward of our planet and creating a great work environment for our colleagues. I am proud of what we’ve accomplished so far and deeply grateful to our global team for their passion for fulfilling our Mission and delivering on our commitments to society.”

Highlights of the report include:

Communities

  • Collectively volunteered more than 100,000 hours to support communities around the world.
  • Reached more than 60,000 students through the Thermo Fisher Scientific Junior Innovators Challenge in partnership with the Society for Science, the premier STEM competition for middle schoolers in the U.S.
  • Established collaborations with the National Quality Minority Forum, to increase diversity in clinical trials, and Project HOPE, to advance health equity among HIV-positive youth in sub-Saharan Africa.

Environment

  • Achieved key milestones toward the company’s goal of net-zero emissions by 2050, including the sourcing 41% of global electricity from renewable energy.
  • Announced a new agreement to power over half of Thermo Fisher’s European footprint with 100% renewable energy by 2025.
  • Established new commitment to achieve 80% renewable electricity utilization globally by 2030.

Colleagues

  • Advanced our vibrant and inclusive culture where colleagues’ unique backgrounds and perspectives are embraced.
  • Continued to develop the workforce, including launching new training programs for emerging technologies and an internal generative AI platform.
  • Enhanced global access to wellness resources.

In reporting its CSR progress, the company considers internationally recognized standards, guidelines and reference frameworks, including the Global Reporting Initiative (GRI) Standards, the IFRS Foundation’s SASB Standards, the Task Force on Climate-related Financial Disclosures (TCFD) and the United Nations Sustainable Development Goals (SDGs). Thermo Fisher makes additional topic-specific ESG data available to key stakeholders through its annual CDP report and voluntary disclosure of EEO-1 information.

Learn more at www.thermofisher.com/CSR.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

C4 Therapeutics

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Amneal Pharmaceuticals

Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB